Articles tagged "T cells"

2019 American Transplant Congress
IL-1β and IL-6 Facilitate T Cell Reconstitution in Heart Allograft Recipients Treated with Anti-Thymocyte Globulin
S. Hasgur, R. Fan, A. Valujskikh
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Antibody-mediated lymphocyte depletion is used in solid organ and stem cell transplantation. However, T cell reconstitution after lymphoablation may lead to acute rejection and…
2019 American Transplant Congress
Thymoglobulin Induction with Tacrolimus and Everolimus Maintenance Therapy in Elderly Kidney Transplantation Results in Prolonged Lymphocyte Depletion and Do Not Favor Regulatory Profile
E. David-Neto¹, G. Ramos de Freitas¹, M. Fernandes¹, F. Agena¹, F. Brambate Carvalhinho Lemos¹, F. Jota de Paula¹, V. Coelho², N. Zocoler Galante¹
¹Renal Transplantation Service, Hospital das Clínicas - University of São Paulo School of Medicine, Sao Paulo, Brazil, ²Laboratory of Immunology – LIM 19, Heart Institute - University of São Paulo School of Medicine, Sao Paulo, Brazil
*Purpose: Despite the growing number of elderly kidney transplant (Ktx) recipientes few studies describe the effects of immunosuppression on this group. We evaluated the immunological…
2019 American Transplant Congress
The Effects of Chronic Kidney Disease on Antiviral T Cell Response
R. L. Crepeau¹, H. Li², L. P. Daley-Bauer³, M. L. Ford¹, P. D. Winterberg²
¹Emory Transplant Center, Atlanta, GA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Microbiology & Immunology, Emory University School of Medicine, Atlanta, GA
*Purpose: Accumulation of memory T cells bearing markers of sustained antigen stimulation have been described in patients with chronic kidney disease (CKD). Cytomegalovirus (CMV) establishes…
2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
V. H. Ferreira¹, C. J. Guidos², A. Humar¹, D. Kumar¹
¹UHN, Toronto, ON, Canada, ²SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…
2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
A. Gil¹, M. Co², M. Calvo-Calle¹, J. Cruz¹, L. Stern¹, L. Gibson²
¹Pathology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…
2019 American Transplant Congress
TACI Polymorphisms Associated with Increased Alloimmunity and Allograft Rejection
M. Garcia de Mattos-Barbosa¹, E. A. Farkash², J. L. Platt¹, M. Cascalho¹
¹Transplant Surgery, University of Michigan, Ann Arbor, MI, ²Pathology, University of Michigan, Ann Arbor, MI
*Purpose: Transmembrane activator and CAML interactor (TACI) controls B cell differentiation. The TACI gene is highly polymorphic (>95% of all genes) and frequently variants exhibit…
2019 American Transplant Congress
Examination of a Novel Immunoregulatory Marker in Kidney and Lung Transplant Recipients
A. D. Desai¹, G. J. Kavalam², A. Chandraker², S. Tripathi²
¹1Harvard Summer Research Program for Kidney Medicine, Harvard Medical School,, Boston, MA, ²Schuster Family Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
*Purpose: The T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor mainly expressed on T cells and NK cells. TIGIT has…
2019 American Transplant Congress
Immunologically Tolerant Liver Transplant Recipients Are Characterized by Donor-Specific Hypo Responsiveness of Circulating T-cells
A. A. Duizendstra¹, R. J. Knegt de¹, M. G. Betjes², M. P. Peppelenbosch¹, N. H. Litjens², J. Kwekkeboom¹
¹Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
*Purpose: Lifelong treatment with immunosuppressive drugs (IS) to prevent graft rejection in transplant recipients is accompanied by side effects. Some recipients are considered to be…
2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
W. Zhang, J. Robertson, G. Karadkhele, B. Johnson, C. Larsen
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…
2019 American Transplant Congress
Differences in CMV-Specific CD4 T Cell Population in De Novo Kidney Transplant Recipients Treated with Everolimus-Based Regimen Compared to a Standard Tacrolimus-MPA Regimen: Results from ATHENA
I. A. Hauser¹, S. Marx¹, C. Sommerer¹, B. Suwelack¹, D. Dragun¹, O. Witzke¹, F. Lehner¹, I. Kroeger², M. Junge², F. Thaiss¹, B. Nashan¹, M. Sester¹
¹ATHENA, CMV Substudy Group, Germany, ²Novartis, Pharma GmbH, Germany
*Purpose: The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic…